Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Next Previous
Trial Profile

A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms RE-VERSE AD
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Nippon Boehringer Ingelheim

Most Recent Events

  • 01 Sep 2021 Results of sub-analysis assessing anticoagulation reversal and clinical outcomes in dabigatran treated patients requiring urgent surgery or procedural intervention published in the Annals of Surgery
  • 08 Oct 2019 Results assessing the extent of reversal and outcomes according to baseline renal function in dabigatran-treated nondialysis patients receiving idarucizumab, published in the Journal of the American College of Cardiology
  • 03 May 2019 Results analysing the pharmacokinetics of idarucizumab and its target dabigatran in bleeding/surgical patients published in the Journal of Thrombosis and Haemostasis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top